Although the proportion of the cancer mutations in PRKAA2 that cause loss-of-function is not yet clear, the occurrence of frequent mutations suggests that, if anything, AMPK-α2 is acting as a tumour suppressor. Here, PRKAA2 is linked to neoplasm.